Primary Replacement Option

The American Academy of Sleep Medicine recommends clonidine as a first-line replacement for prazosin in treating PTSD-related nightmares, with a starting dose of 0.1 mg twice daily, due to its similar therapeutic mechanism of reducing CNS adrenergic activity 1, 2, 3, 4
Clonidine has demonstrated specific efficacy in female civilian PTSD patients, with a 2-week pilot study showing a decrease in nightmare frequency 3, 4
The American Academy of Sleep Medicine designates clonidine as Level C evidence for PTSD-associated nightmares, with a recommendation to start with 0.1 mg twice daily and titrate to 0.2 mg/day average dose based on response and tolerability 1, 2, 5

Secondary Pharmacological Options

Risperidone 0.5-2.0 mg/day is an effective alternative, with 80% of patients reporting improvement in nightmares, and no significant side effects reported 6, 3, 4
Aripiprazole 15-30 mg/day is also an option, with four of five veterans showing substantial improvement in nightmares at 4 weeks, and a better tolerability profile compared to olanzapine 6, 3, 4

The American Academy of Sleep Medicine recommends a treatment algorithm starting with clonidine 0.1 mg twice daily, followed by risperidone 0.5-2.0 mg/day if clonidine is ineffective or not tolerated, and then aripiprazole 15-30 mg/day if risperidone is ineffective or not tolerated 1, 2, 3, 4, 6

Monitor blood pressure carefully with both clonidine and trazodone, as orthostatic hypotension is a significant concern 1, 2, 5
Avoid nefazodone as first-line therapy due to increased hepatotoxicity risk 1, 2, 5
Expect return of nightmares if medication is discontinued, as discontinuation typically leads to return to baseline intensity 7

The American Academy of Sleep Medicine recommends starting risperidone at 0.5-2.0 mg at bedtime for PTSD-related nightmares, with most patients achieving optimal benefit at 2 mg nightly, and 80% of patients reporting improvement after the first dose 8
The American Academy of Sleep Medicine evidence shows effective dosing ranges from 0.5-2.0 mg/day for nightmare treatment 8

80% of patients report improvement after the first use of risperidone for nightmares, with total cessation of nightmare recall often occurring within 1-2 days at 2 mg dosing 8
By 6 weeks, expect statistically significant reductions in nightmare frequency and severity scores, with the average maximum effective dose in a 12-week trial being 2.3 ± 0.6 mg (range 1-3 mg) per day 8, 9

Nightmare treatment requires substantially lower doses (0.5-3 mg) than psychotic disorders, with the mechanism for nightmare suppression operating at lower doses than dopamine blockade 8, 9
No significant side effects were reported in the nightmare treatment studies at doses of 0.5-3 mg/day, but monitor for extrapyramidal symptoms if doses approach or exceed 2 mg/day 8, 9
Aripiprazole 15-30 mg/day represents a third-line option with better tolerability than olanzapine 9

The American Academy of Sleep Medicine recommends olanzapine, cyproheptadine, fluvoxamine, gabapentin, nabilone, phenelzine, topiramate, trazodone, and tricyclic antidepressants as options for PTSD-associated nightmares, although with less robust evidence 10
The American Academy of Sleep Medicine specifically recommends against clonazepam and venlafaxine for nightmare disorder 10